Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in pulmonary embolism swept away in favor of mechanical thrombectomy. A ...
The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been announced this year. It also is ...
At this year’s AACR-NCI-EORTC conference, several presentations brought to light new ways to tackle the treatment of genomically unstable cancers. Genomically unstable cancers can be treated by ...
Inhibrx said the encouraging results in treating the rare, slow growing cancer that often begins in the bone, bolster its plans to file a BLA in the second quarter of 2026. The company’s stock (NASDAQ ...
Sustaining healthy weight loss is about so much more than cutting calories or injecting drugs, as many GLP-1 users are ...
During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...
Preclinical results were recently presented from studies conducted by Fulcrum Therapeutics Inc. evaluating FTX-6274, a novel, ...
Activating the glucagon-like peptide 1 receptor (GLP-1R) is the mechanism of action of most drugs currently used to treat ...
Mode Sensors AS received U.S. FDA 510(k) clearance for its Re:Balans hydration monitoring system. The wearable patch sensor ...
Adocia SA is looking to further apply its Biochaperone formulation technology to metabolic disorders, Olivier Soula, Adocia ...
India’s Central Drugs Standard Control Organization (CDSCO) posted a draft guidance for medical device software, providing ...
The multidrug resistance of methicillin-resistant Staphylococcus aureus (MRSA) makes it a global threat to public health, and the current first-line treatment for MRSA, the glycopeptide vancomycin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback